Tech Company Financing Transactions
Scinai Immunotherapeutics Funding Round
Scinai Immunotherapeutics, based in Jerusalem, secured $1.4 million from private investors.
Transaction Overview
Company Name
Announced On
6/12/2025
Transaction Type
Venture Equity
Amount
$1,380,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Jerusalem BioPark, Hadassah Ein Kerem campus
Jerusalem, Undisclosed
Israel
Jerusalem, Undisclosed
Israel
Phone
Website
Email Address
Overview
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amir Reichman
Browse more venture capital transactions:
Prev: 6/12/2025: Tastewise venture capital transaction
Next: 6/12/2025: GrailPay venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs